Condition
Therapeutic Plasma Exchange
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
80% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04685655Not ApplicableTerminatedPrimary
RescuE pLAsma eXchange in Severe COVID-19
NCT06652516Not ApplicableCompletedPrimary
Comparison Between Centrifugation Based and Membrane Based Plasma Exchange
NCT04351438CompletedPrimary
Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
NCT03888417CompletedPrimary
TPE in Rennes Hospital
NCT05191394Not ApplicableCompletedPrimary
IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.
Showing all 5 trials